iDose TR (travoprost intracameral implant) offers the reduction of intraocular pressure (IOP). It treats patients with ocular hypertension (OHT) or open-angle glaucoma (OAG). The first-of-its-kind, long-duration, intracameral procedural pharmaceutical therapy. It continuously delivers 24/7 therapeutic levels of travoprost inside the eye for extended periods.

Glaukos designed iDose TR to improve the standard of care by addressing patient non-compliance issues. The implant also addresses the chronic side effects associated with topical glaucoma medications. iDose TR won FDA approval in late 2023.